However, comparisons of clinical parameters indicated a trend toward more advanced disease in NAb− CLL vaccinees, with higher Rai stage, increased serum β2M levels, and IVIg requirements that were absent in NAb+ CLL vaccinees (Figure 4F). The gene discussed is B2M; the disease is B-cell chronic lymphocytic leukemia.